<DOC>
	<DOCNO>NCT01537029</DOCNO>
	<brief_summary>To determine effect weight doxorubicin cyclophosphamide plasma clearance participant normal weight ( body mass index [ BMI ] &lt; 25 kg/m2 , overweight class I obese ( BMI 25-34.9 kg/m2 ) , class II-III obese ( BMI â‰¥ 35 kg/m2 ) . The hypothesis participant weigh high doxorubicin cyclophosphamide clearances participant weigh less . Restated , area drug-concentration time profile , also know AUC , participant decrease participant weight increase .</brief_summary>
	<brief_title>Effect Weight Population Pharmacokinetic Analysis Doxorubicin Cyclophosphamide</brief_title>
	<detailed_description>This single site study conduct UT Southwestern Simmons Cancer Center . This study design measure drug concentration blood 18 female breast cancer patient require doxorubicin ( 30 minute infusion ) cylcophosphamide ( 30 minute infusion ) part standard medical care . Up total 40 adult female participant consent study cancer center . Eighteen participant need complete study . The others likely screen failure . The participant 100 ml blood drawn via peripheral intravenous catheter prior doxorubicin infusion , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 5 , 12-24 , 24-72 h begin doxorubicin infusion . The 5 hour blood draw optional . The intravenous catheter remove participant discharged cancer center day 1 . The participant ask return cancer center 12-24 24-72 hour final 2 blood draw conduct . The participant must treat Doxurubicin Cyclophosphamide order participate pharmacokinetic analysis study .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Females , age 18 year age old , racial ethnic origin schedule receive first cycle single intravenous dose doxorubicin ( 30 minute infusion ) cylcophosphamide ( 30 minute infusion ) part standard medical care breast cancer . English and/or Spanish speaking participant eligible participate . Pregnant nursing unwilling use reliable contraception method study . The effect doxorubicin cyclophosphamide pregnancy unknown . In addition , metabolic change accompany pregnancy may alter concentrationtime profile doxorubicin cyclophosphamide , pregnancy postpartum state would confound variable . Participants unwilling comply study procedure . CrCl &lt; 10 ml/min Participants require peritoneal hemodialysis Serum bilirubin &gt; 1.19 mg/dL Receipt follow drug : ) Alter doxorubicin concentration : carbamazepine , cyclosporine , fosphenytoin , paclitaxel , phenytoin , sorafenib , valspodar , verapamil ; b ) Alter cyclophosphamide concentration : cyclosporine , nevirapine , ondansetron ; c ) All drug review screen patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Obesity</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Weight</keyword>
</DOC>